American Diabetes Association
Browse
DC22-0784 Supplemental_Materials_R1.docx (47.28 kB)

Long-Term Outcomes Among Young Adults with Type 2 Diabetes Based on Durability of Glycemic Control: Results from the TODAY Cohort Study

Download (47.28 kB)
figure
posted on 2022-10-03, 16:42 authored by Janine Higgins, Steven D. Chernausek, Laure El ghormli, Elvira Isganaitis, Megan M. Kelsey, Marsha D Marcus, Siripoom McKay, Maggie Siska, Shylaja Srinivasan, Rose Gubitosi-Klug, The TODAY Study Group

  

Objective: To examine the effect of different patterns of durable glycemic control on the development of comorbidities among youth with type 2 diabetes and to assess the impact of fasting glucose variability on the clinical course of type 2 diabetes.

Research Design and Methods: 457 TODAY participants, mean age 14 years and diabetes duration <2 years at entry, and a minimum study follow-up of 10 years were included in these analyses. HbA1c, fasting glucose concentrations, and beta-cell function estimates from oral glucose tolerance tests were measured longitudinally. Prevalence of comorbidities by glycemic control status after 10 years in the TODAY study was assessed.

Results: Higher baseline HbA1c concentration, lower beta-cell function, and maternal history of diabetes were strongly associated with loss of glycemic control in youth with type 2 diabetes. Higher cumulative HbA1c concentration over 4 years and greater fasting glucose variability over a year’s time within 3 years of diagnosis were related to higher prevalence of dyslipidemia, nephropathy, and retinopathy progression over the subsequent 10 years. A coefficient of variability in fasting glucose at or above 8.3% predicted future loss of glycemic control and development of comorbidities.

Conclusions: Higher baseline HbA1c concentration and fasting glucose variability during year 1 accurately predicted youth with type 2 diabetes who will experience metabolic decompensation and comorbidities and may be useful tools for clinicians when considering early intensification of therapy.

Funding

U.S. Department of Health and Human Services > National Institutes of Health

NIDDK

U.S. Department of Health and Human Services > National Institutes of Health > NIH Office of the Director U01-DK61212 U01-DK61230 U01-DK61239 U01-DK61242 U01-DK61254

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC